Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy

被引:10
作者
Wang, Wenyan [1 ]
Wang, Xin [2 ]
Liu, Jiaqi [2 ]
Zhu, Qiang [1 ]
Wang, Xiang [2 ]
Wang, Pilin [1 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Breast Surg, Beijing 100070, Peoples R China
[2] Chinese Acad Med Sci, Dept Breast Surg Oncol, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Neoadjuvant chemotherapy; Lymph node; Pathological response; Nomogram; PREOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; BIOPSY; THERAPY; SURGERY; IDENTIFICATION; ADJUVANT; IMPACT; TUMORS;
D O I
10.1097/CM9.0000000000001876
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pathological complete response (pCR) of axillary lymph nodes (ALNs) is frequently achieved in patients with clinically node-positive breast cancer after neoadjuvant chemotherapy (NAC), and ALN status is an important prognostic factor for breast cancer patients. This study aims to develop a new predictive clinical model to assess the ALN pCR rate after NAC. Methods: This was a retrospective series of 467 patients who had biopsy-proven positive ALNs at diagnosis and underwent ALN dissection from 2007 to 2014 at the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences. We analyzed the clinicopathologic features of the patients and developed a nomogram to predict the probability of ALN pCR. A multivariable logistic regression stepwise model was used to construct a nomogram to predict ALN pCR in node-positive patients. The adjusted area under the receiver operating characteristic curve (AUC) was calculated to quantify the ability to rank patients by risk. Internal validation was performed using the 50/50 hold-out validation method. The nomogram was externally validated with prospective cohorts of 167 patients from 2016 to 2018 at the Cancer Hospital of the Chinese Academy of Medical Sciences and 114 patients from 2018 to 2020 at Beijing Tiantan Hospital. Results: In this retrospective study, 115 (24.6%) patients achieved ALN pCR after NAC. Multivariate analysis showed that clinical tumor stage (Odds ratio [OR]: 0.321, 95% confidence interval [CI]: 0.121-0.856; P = 0.023); primary tumor response (OR: 0.189; 95% CI: 0.123-0.292; P < 0.001), and estrogen receptor status (OR: 0.530, 95% CI: 0.304-0.925; P = 0.025) were independent predictors of ALN pCR. The nomogram was constructed based on the result of multivariate analysis. In the internal validation of performance of nomogram, the AUCs for the training and test sets were 0.719 and 0.753, respectively. The nomogram was validated in external cohorts with AUCs of 0.720, which demonstrated good discriminatory power in these data sets. Conclusion: We developed a nomogram to predict the likelihood of axillary pCR in node-positive breast cancer patients after NAC. The predictive model performed well in multicenter prospective external validation. This practical tool could provide information to surgeons regarding whether to perform additional ALN dissection after NAC.
引用
收藏
页码:333 / 340
页数:8
相关论文
共 34 条
[1]   AXILLARY DISSECTION OF LEVEL-I AND LEVEL-II LYMPH-NODES IS IMPORTANT IN BREAST-CANCER CLASSIFICATION [J].
AXELSSON, CK ;
MOURIDSEN, HT ;
ZEDELER, K .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (8-9) :1415-1418
[2]   Nomograms in oncology: more than meets the eye [J].
Balachandran, Vinod P. ;
Gonen, Mithat ;
Smith, J. Joshua ;
DeMatteo, Ronald P. .
LANCET ONCOLOGY, 2015, 16 (04) :E173-E180
[3]   Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study [J].
Boileau, Jean-Francois ;
Poirier, Brigitte ;
Basik, Mark ;
Holloway, Claire M. B. ;
Gaboury, Louis ;
Sideris, Lucas ;
Meterissian, Sarkis ;
Arnaout, Angel ;
Brackstone, Muriel ;
McCready, David R. ;
Karp, Stephen E. ;
Trop, Isabelle ;
Lisbona, Andre ;
Wright, Frances C. ;
Younan, Rami J. ;
Provencher, Louise ;
Patocskai, Erica ;
Omeroglu, Atilla ;
Robidoux, Andre .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :258-U150
[4]   Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) [J].
Boughey, Judy C. ;
Ballman, Karla V. ;
Le-Petross, Huong T. ;
McCall, Linda M. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Feliberti, Eric C. ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2016, 263 (04) :802-807
[5]   Factors Affecting Sentinel Lymph Node Identification Rate After Neoadjuvant Chemotherapy for Breast Cancer Patients Enrolled in ACOSOG Z1071 (Alliance) [J].
Boughey, Judy C. ;
Suman, Vera J. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Flippo-Morton, Teresa S. ;
Kuerer, Henry M. ;
Bowling, Monet ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2015, 261 (03) :547-552
[6]   Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial [J].
Boughey, Judy C. ;
McCall, Linda M. ;
Ballman, Karla V. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Flippo-Morton, Teresa ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2014, 260 (04) :608-616
[7]   Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial [J].
Boughey, Judy C. ;
Suman, Vera J. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Kuerer, Henry M. ;
Bowling, Monet ;
Flippo-Morton, Teresa S. ;
Byrd, David R. ;
Ollila, David W. ;
Julian, Thomas B. ;
McLaughlin, Sarah A. ;
McCall, Linda ;
Symmans, W. Fraser ;
Le-Petross, Huong T. ;
Haffty, Bruce G. ;
Buchholz, Thomas A. ;
Nelson, Heidi ;
Hunt, Kelly K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14) :1455-1461
[8]   Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis [J].
Broglio, Kristine R. ;
Quintana, Melanie ;
Foster, Margaret ;
Olinger, Melissa ;
McGlothlin, Anna ;
Berry, Scott M. ;
Boileau, Jean-Francois ;
Brezden-Masley, Christine ;
Chia, Stephen ;
Dent, Susan ;
Gelmon, Karen ;
Paterson, Alexander ;
Rayson, Daniel ;
Berry, Donald A. .
JAMA ONCOLOGY, 2016, 2 (06) :751-760
[9]   Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection [J].
Caudle, Abigail S. ;
Yang, Wei T. ;
Krishnamurthy, Savitri ;
Mittendorf, Elizabeth A. ;
Black, Dalliah M. ;
Gilcrease, Michael Z. ;
Bedrosian, Isabelle ;
Hobbs, Brian P. ;
DeSnyder, Sarah M. ;
Hwang, Rosa F. ;
Adrada, Beatriz E. ;
Shaitelman, Simona F. ;
Chavez-MacGregor, Mariana ;
Smith, Benjamin D. ;
Candelaria, Rosalind P. ;
Babiera, Gildy V. ;
Dogan, Basak E. ;
Santiago, Lumarie ;
Hunt, Kelly K. ;
Kuerer, Henry M. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1072-+
[10]   The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis [J].
Chen, Xianyu ;
He, Chao ;
Han, Dongdong ;
Zhou, Meirong ;
Wang, Quan ;
Tian, Jinhui ;
Li, Lun ;
Xu, Feng ;
Zhou, Enxiang ;
Yang, Kehu .
FUTURE ONCOLOGY, 2017, 13 (09) :843-857